Regulatory Updates
🇺🇸 FDA Page 4FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 37–48 of 382 articles
FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease
FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
Vertex launches Journavx after FDA approval for acute pain
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer
FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
Facet Life Sciences Appoints Frank Closurdo as VP, Commercial Services
Amneal Romidepsin FDA Approval: B2B Analysis for BD Teams and Investors